Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 4/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410580 | 1.00 | PPARA (0.49) | PPARAL3MBTL1PPARGSLC15A1SLC1A1 | |
| SCHEMBL2410585 | 1.00 | PPARA (0.49) | PPARAL3MBTL1PPARGSLC15A1SLC1A1 | |
| SCHEMBL14243701 | 0.94 | L3MBTL1 (0.51) | PPARAL3MBTL1PPARGSLC15A1SLC1A1 | |
| SCHEMBL15684087 | 0.94 | L3MBTL1 (0.51) | PPARAL3MBTL1PPARGSLC15A1SLC1A1 | |
| SCHEMBL7422742 | 0.92 | L3MBTL1 (0.53) | PPARAL3MBTL1PPARGSLC15A1SLC1A1 | |
| SCHEMBL2413866 | 0.89 | PPARA (0.46) | PPARAL3MBTL1PPARGMMP3MMP9 | |
| SCHEMBL2413872 | 0.89 | PPARA (0.46) | PPARAL3MBTL1PPARGMMP3MMP9 | |
| SCHEMBL1914958 | 0.83 | CTSS (0.46) | PPARGMMP3CTSSCA2CA9 | |
| SCHEMBL1914954 | 0.83 | CTSS (0.46) | PPARGMMP3CTSSCA2CA9 | |
| SCHEMBL1915090 | 0.83 | CTSS (0.46) | PPARGMMP3CTSSCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | PPARA 1196/4885L3MBTL1 1545/4885PPARG 1321/4885 |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | CYP3A7, CYP2C19, CYP3A5 | PPARA 661/4885L3MBTL1 4739/4885PPARG 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.